Longitudinal Molecular Response Monitoring with ctDNA in ADC-Treated Solid Tumors

• Presenting new data to track ctDNA molecular response against clinical outcome to assess how early blood-based dynamics reflect treatment benefit in patients receiving ADCs
• Examining how longitudinal monitoring performs across a pan-tumor population, highlighting where molecular response adds value beyond standard imaging
• Discusses practical implications for using molecular response to inform clinical development strategy and therapeutic decision making in ADC programs

Speakers:

Qu Zhang

Scientific Director, Precision Medicine Solid Tumor

Abbvie